201 related articles for article (PubMed ID: 32365663)
1. Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.
Karai E; Szebényi K; Windt T; Fehér S; Szendi E; Dékay V; Vajdovich P; Szakács G; Füredi A
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365663
[TBL] [Abstract][Full Text] [Related]
2. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
4. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
[TBL] [Abstract][Full Text] [Related]
6. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
7. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
10. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway.
Cordo Russo RI; García MG; Alaniz L; Blanco G; Alvarez E; Hajos SE
Int J Cancer; 2008 Mar; 122(5):1012-8. PubMed ID: 17985348
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance.
Lee JJ; Hughes CS; Fine RL; Page RL
Cancer; 1996 May; 77(9):1892-8. PubMed ID: 8646690
[TBL] [Abstract][Full Text] [Related]
14. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Findling-Kagan S; Sivan H; Ostrovsky O; Nagler A; Galski H
Leuk Res; 2005 Apr; 29(4):407-14. PubMed ID: 15725475
[TBL] [Abstract][Full Text] [Related]
16. The role of MDR-1 in refractory lymphoma.
Sandor V; Wilson W; Fojo T; Bates SE
Leuk Lymphoma; 1997 Dec; 28(1-2):23-31. PubMed ID: 9498700
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
18. Development of multidrug resistance in a canine lymphoma cell line.
Uozurmi K; Nakaichi M; Yamamoto Y; Une S; Taura Y
Res Vet Sci; 2005 Jun; 78(3):217-24. PubMed ID: 15766940
[TBL] [Abstract][Full Text] [Related]
19. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
20. The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo.
Huang C; Huang S; Li H; Li X; Li B; Zhong L; Wang J; Zou M; He X; Zheng H; Si X; Liao W; Liao Y; Yang L; Bin J
J Exp Clin Cancer Res; 2018 Sep; 37(1):232. PubMed ID: 30231924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
